Bank of New York Mellon Corp boosted its position in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 134.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,053 shares of the biopharmaceutical company’s stock after purchasing an additional 7,496 shares during the quarter. Bank of New York Mellon Corp’s holdings in GW Pharmaceuticals PLC- were worth $1,822,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Victory Capital Management Inc. raised its holdings in GW Pharmaceuticals PLC- by 2.5% during the 2nd quarter. Victory Capital Management Inc. now owns 306,510 shares of the biopharmaceutical company’s stock worth $42,770,000 after purchasing an additional 7,535 shares during the last quarter. TD Asset Management Inc. raised its holdings in GW Pharmaceuticals PLC- by 36.5% during the 2nd quarter. TD Asset Management Inc. now owns 23,076 shares of the biopharmaceutical company’s stock worth $3,220,000 after purchasing an additional 6,176 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in GW Pharmaceuticals PLC- during the 2nd quarter worth about $481,000. Rothschild Investment Corp IL raised its holdings in GW Pharmaceuticals PLC- by 70.5% during the 2nd quarter. Rothschild Investment Corp IL now owns 20,332 shares of the biopharmaceutical company’s stock worth $2,837,000 after purchasing an additional 8,405 shares during the last quarter. Finally, Wells Fargo & Company MN raised its holdings in GW Pharmaceuticals PLC- by 20.6% during the 1st quarter. Wells Fargo & Company MN now owns 29,172 shares of the biopharmaceutical company’s stock worth $3,288,000 after purchasing an additional 4,987 shares during the last quarter. 75.44% of the stock is owned by hedge funds and other institutional investors.

Shares of GWPH stock opened at $143.32 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.67 and a quick ratio of 8.21. The stock has a market capitalization of $4.80 billion, a PE ratio of -20.62 and a beta of 2.61. GW Pharmaceuticals PLC- has a one year low of $101.07 and a one year high of $179.65.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) EPS for the quarter, beating analysts’ consensus estimates of ($2.40) by $1.14. The company had revenue of $3.46 million during the quarter, compared to analysts’ expectations of $2.00 million. GW Pharmaceuticals PLC- had a negative return on equity of 47.65% and a negative net margin of 1,392.61%. As a group, sell-side analysts expect that GW Pharmaceuticals PLC- will post -9.11 earnings per share for the current fiscal year.

Several brokerages have weighed in on GWPH. Bank of America reissued a “buy” rating and set a $197.00 price objective (up from $181.00) on shares of GW Pharmaceuticals PLC- in a report on Friday, September 28th. Morgan Stanley upped their price target on GW Pharmaceuticals PLC- from $197.00 to $240.00 and gave the company an “overweight” rating in a research note on Friday, September 28th. Cantor Fitzgerald set a $211.00 price target on GW Pharmaceuticals PLC- and gave the company a “buy” rating in a research note on Thursday, September 27th. BidaskClub raised GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a research note on Saturday, September 22nd. Finally, Zacks Investment Research raised GW Pharmaceuticals PLC- from a “hold” rating to a “strong-buy” rating and set a $168.00 price target for the company in a research note on Wednesday. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $185.00.

GW Pharmaceuticals PLC- Profile

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Featured Article: How Do You Calculate Return on Equity (ROE)?

Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.